# US 2024/0197688 A1 · Combination medicine for preventing/treating dyslipidemia or cardiovascular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197688 A1
- Document ID: US20240197688A1
- Status: Published application
- Kind: A1
- Application number: 18/287,809
- Filed: 2022-04-19
- Published: 2024-06-20
- Earliest claimed: 2021-04-20
- Assignees: Kowa Company, Ltd.
- Applicants: Kowa Company, Ltd.
- Inventors: Noriyuki INOUE; Kenji SAITO; Toshiaki TAKIZAWA
- Web page: https://patentgrep.com/patent/US20240197688A1

## CPC

- A61K 31/423: condensed with carbocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention addresses the problem of providing a pharmaceutical composition/drug combination which makes it possible to prevent and/or treat dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist and an ATP citrate lyase (ACL) inhibitor for preventing and/or treating dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events.

## Claims

### Claim at position 1

-5. (canceled)

### Claim 6

A method for preventing and/or treating dyslipidemia or cardiovascular disease, comprising: a step of administering an effective amount of a PPARα agonist and an effective amount of an ACL inhibitor to a subject in need of treatment.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the dyslipidemia is hypercholesterolemia or hypertriglyceridemia.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the cardiovascular disease is arteriosclerosis or a cardiovascular event.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the PPARα agonist is (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, or a salt, or a solvate, or a solvate of the salt thereof.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the ACL inhibitor is 8-hydroxy-2,2,14, 14-tetramethylpentadecanedioic acid, or a salt, or a solvate, or a solvate of the salt thereof.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the ACL inhibitor is 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, or a salt, or a solvate, or a solvate of the salt thereof.
